secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0000950170-25-003286
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics reports $107.6M cash; Phase 2a RIVER completed enrollment; CORAL 80% enrolled
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities estimated at $107.6M as of Dec 31, 2024; runway into H2 2026.
- Last patient completed final visit in Phase 2a RIVER trial (RCC); topline results expected Q1 2025.
- Phase 2b CORAL trial (IPF chronic cough) now ~80% enrolled after positive SSRE; topline expected H1 2025.
- SSRE analysis in Dec 2024 reaffirmed original sample size of N=160 for CORAL trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017025003286/0000950170-25-003286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017025003286/trvi-20250108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-003286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer